Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.
Trancart S, Charreau I, Marchou B, Bocquentin M, Molina JM, Izopet J, Tangre P, Aboulker JP, Taburet AM; ANRS 106 Study Group. Trancart S, et al. Among authors: tangre p. Antimicrob Agents Chemother. 2012 Mar;56(3):1655-7. doi: 10.1128/AAC.05452-11. Epub 2011 Dec 27. Antimicrob Agents Chemother. 2012. PMID: 22203586 Free PMC article. Clinical Trial.
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.
Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, Tangre P, Aboulker JP, Taburet AM, Molina JM, Massip P, Marchou B, Izopet J; ANRS 106-Window Study Team. Delobel P, et al. Among authors: tangre p. PLoS One. 2011;6(6):e21655. doi: 10.1371/journal.pone.0021655. Epub 2011 Jun 27. PLoS One. 2011. PMID: 21738752 Free PMC article. Clinical Trial.
Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.
Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM; ANRS 106 Study Group. Bouldouyre MA, et al. Among authors: tangre p. J Acquir Immune Defic Syndr. 2009 Dec;52(5):531-7. doi: 10.1097/QAI.0b013e3181be73e3. J Acquir Immune Defic Syndr. 2009. PMID: 19855285 Clinical Trial.
Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial.
Charreau I, Jeanblanc G, Tangre P, Boyer L, Saouzanet M, Marchou B, Molina JM, Aboulker JP, Durand-Zaleski I; ANRS 106 Study Group. Charreau I, et al. Among authors: tangre p. J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):416-21. doi: 10.1097/QAI.0b013e31818a657c. J Acquir Immune Defic Syndr. 2008. PMID: 18931625 Clinical Trial.
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922
12 results